Pascal Soriot

Pascal Soriot is the CEO of AstraZeneca, one of the world's largest biopharmaceutical companies, headquartered in Cambridge, United Kingdom. Born in 1959 in France, Soriot is a trained veterinarian who transitioned into pharmaceutical management, spending 20 years at Roche in progressively senior roles including head of the pharmaceutical division before joining AstraZeneca as CEO in October 2012. When Soriot arrived at AstraZeneca, the company was widely considered a takeover target facing existential decline. Multiple blockbuster drugs were losing patent protection simultaneously, revenue was falling sharply, and Pfizer launched a hostile $118 billion acquisition bid in 2014. Soriot rejected the bid, convincing the board and shareholders that AstraZeneca could rebuild its pipeline and grow independently — a bet that has been vindicated spectacularly. AstraZeneca's market capitalization has grown from roughly $60 billion to over $250 billion during his tenure. The centerpiece of Soriot's turnaround is AstraZeneca's oncology franchise, which he built into one of the industry's strongest through internal R&D investment and strategic acquisitions. Key cancer drugs including Tagrisso (lung cancer), Imfinzi (multiple cancers), and Enhertu (developed with Daiichi Sankyo for HER2-positive cancers) have become multi-billion-dollar franchises. Beyond oncology, he has strengthened AstraZeneca's positions in cardiovascular/renal/metabolic diseases (Farxiga) and rare diseases (through the Alexion acquisition for $39 billion in 2021). Soriot's most public-facing moment came during the COVID-19 pandemic, when AstraZeneca partnered with Oxford University to develop a viral vector vaccine. Crucially, Soriot pledged to supply the vaccine at cost during the pandemic — a decision that saved millions of lives globally but generated controversy over supply delays and rare blood clotting side effects. The pandemic episode cemented Soriot's reputation as a pharmaceutical leader willing to prioritize public health alongside shareholder value.